Table 3.
Clinical, electrocardiographic and electrocardiographic characteristics associated with anthracycline induced cardiotoxicity
| Variable | Anthracycline induced cardiotoxicity |
Chi square (X2) |
p-value | ||
| Cardiotoxicity | No Cardiotoxicity | ||||
| (N=14) | (N=50) | ||||
| Gender | Male | 0 (0.00%) | 14 (28.00%) | 5.02 | 0.025 |
| Female | 14 (100.00%) | 36 (74.00%) | |||
| Age (years) | 18–49 | 10(71.4) | 33(66.0) | 0.15 | 0.702 |
| 50–73 | 4(28.6) | 17(34.0) | |||
| Education‡ | Post-primary | 5(35.7) | 24(51.1) | 1.02 | 0.97 |
| Yes | 2 (14.29%) | 9 (18.00%) | |||
| Tobacco smoking | No | 14 (100.00%) | 48 (96.00%) | 0.58 | 0.447 |
| Yes | 0 | 2 (4.00%) | |||
| HIV | No | 13 (92.86%) | 38 (76.00%) | 1.92 | 0.166 |
| Yes | 1 (7.14%) | 12 (24.00%) | |||
| Diabetes | No | 14 (100.00%) | 48 (96.00%) | 0.58 | 0.447 |
| Yes | 0 | 2 (4.00%) | |||
| ECOG | 0 | 5 (35.71%) | 15 (30.00%) | 0.48 | 0.787 |
| 1 | 8 (57.14%) | 33 (66.00%) | |||
| 2 | 1 (7.14) | 2 (4.00%) | |||
| LVEF | <55 | 6 (60.0%) | 4 (40.00%) | 18.7 | <0.001 |
| 55–65 | 8 (33.3%) | 16 (66.7%) | |||
| >65 | 0 (0.00%) | 30 (100%) | |||
| LVFS | <30 | 6 (46.1%) | 7 (53.9%) | 6.43 | 0.040 |
| 30–45 | 8 (14.29%) | 38 (82.6%) | |||
| >45 | 0 (0.00%) | 5 (100.0%) | |||
| E:A | 0.6–1 | 8 (22.9%) | 27 (77.1%) | 0.02 | 0.892 |
| Cumulative dose ‡ | >1 <550mg/m2 | 6 (21.4%) 9(21.4) | 22 (78.6%) 33(78.6) | 0.28 | 0.594 |
| >550mg/m2 | 5(27.8) | 13(72.2) | |||
Statistically significant P<0.05